Berberine Moderates Glucose and Lipid Metabolism through Multipathway Mechanism
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Berberine is known to improve glucose and lipid metabolism disorders, but the mechanism is still under investigation. In this paper, we explored the effects of berberine on the weight, glucose levels, lipid metabolism, and serum insulin of KKAy mice and investigated its possible glucose and lipid‐regulating mechanism. We randomly divided KKAy mice into two groups: berberine group (treated with 250 mg/kg/d berberine) and control group. Fasting blood glucose (FBG), weight, total cholesterol (TC), triglyceride (TG), high‐density lipoprotein‐cholesterol (HDL‐c), low‐density lipoprotein‐cholesterol (LDL‐c), and fasting serum insulin were measured in both groups. The oral glucose tolerance test (OGTT) was performed. RT 2 PCR array gene expression analysis was performed using skeletal muscle of KKAy mice. Our data demonstrated that berberine significantly decreased FBG, area under the curve (AUC), fasting serum insulin (FINS), homeostasis model assessment insulin resistance (HOMA‐IR) index, TC, and TG, compared with those of control group. RT 2 profiler PCR array analysis showed that berberine upregulated the expression of glucose transporter 4 (GLUT4), mitogen‐activated protein kinase 14 (MAPK14), MAPK8(c‐jun N‐terminal kinase, JNK), peroxisome proliferator‐activated receptor α (PPAR α), uncoupling protein 2 (UCP2), and hepatic nuclear factor 4 α(HNF4 α), whereas it downregulated the expression of PPAR γ, CCAAT/enhancer‐binding protein (CEBP), PPAR γ coactivator 1 α(PGC 1 α), and resistin. These results suggest that berberine moderates glucose and lipid metabolism through a multipathway mechanism that includes AMP‐activated protein kinase‐(AMPK‐) p38 MAPK‐GLUT4, JNK pathway, and PPAR α pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 1×
“found that in isolated rat skeletal muscles, metformin stimulates glucose uptake coincident with AMPK activation [33].”
BackgroundAdipocyte differentiation from the inside out
Rosen, E. D., & MacDougald, O. A. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2066 · Cited by 2,607
Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1
Yoon, J. C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C. R., Granner, D. K., et al. (2001) · Nature · doi:10.1038/35093050 · Cited by 1,821
Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391
Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling
SHEPHERD, P. R., WITHERS, D. J., & SIDDLE, K. (1998) · Biochemical Journal · doi:10.1042/bj3330471 · Cited by 953 · cited 1×
“In the insulin signaling pathway, insulin stimulates glucose uptake to muscle and fat tissue [20].”
BackgroundTurner, N., Li, J.-Y., Gosby, A., To, S. W. C., Cheng, Z., Miyoshi, H., Taketo, M. M., Cooney, G. J., Kraegen, E. W., James, D. E., et al. (2008) · Diabetes · doi:10.2337/db07-1552 · Cited by 535 · cited 1×
“…showed that berberine upregulated the expression of glucose transporter 4 (GLUT4), mitogen-activated protein kinase 14 (MAPK14), MAPK8(c-jun N-terminal kinase, JNK), peroxisome proliferator-activated receptor α (PPARα), uncoupling protein 2 (UCP2), and hepatic nuclear factor 4α(HNF4α), whereas…”
BackgroundDUVAL, C., MULLER, M., & KERSTEN, S. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.05.003 · Cited by 199 · cited 1×
“Activation of PPARα results in a reduction of plasma TG levels, which is achieved by induction of genes that decrease the availability of TG for hepatic VLDL secretion and induction of genes that promote lipoprotein lipase-mediated lipolysis of TG-rich plasma lipoproteins [45].”
Background
Cited by
Research progress on berberine with a special focus on its oral bioavailability
Liu, C.-S., Zheng, Y.-R., Zhang, Y.-F., & Long, X.-Y. (2016) · Fitoterapia · doi:10.1016/j.fitote.2016.02.001 · Cited by 363
Berberis Vulgaris and Berberine: An Update Review
Imenshahidi, M., & Hosseinzadeh, H. (2016) · Phytotherapy Research · doi:10.1002/ptr.5693 · Cited by 359
Pirillo, A., & Catapano, A. L. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.09.032 · Cited by 305
Berberine in the treatment of type 2 diabetes mellitus: A systemic review and meta-analysis
Dong, H., Wang, N., Zhao, L., & Lu, F. (2012) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2012/591654 · Cited by 225
Berberine hydrochloride: anticancer activity and nanoparticulate delivery system
Tan, W., Li, Chen, M., & Wang, Y. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s22683 · Cited by 175
Metadata
- Authors
- Zhang, Q., Xiao, X., Feng, K., Wang, T., Li, W., Yuan, T., Sun, X., Sun, Q., Xiang, H., & Wang, H.
- Venue
- Evidence-Based Complementary and Alternative Medicine
- Publisher
- Wiley
- Published
- 2010-09-26
- Volume
- 2011
- Issue
- 1
- ISSN
- 1741-427X (ISSN-L)
- 1741-4288
- OpenAlex
- W1972659108
- Cited by
- 124
- References
- 8
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Berberine Moderates Glucose and Lipid Metabolism through Multipathway Mechanism. https://app.cochat.ai/papers/10.1155/2011/924851
- The paper
- Zhang, Q., Xiao, X., Feng, K., Wang, T., Li, W., Yuan, T., Sun, X., Sun, Q., Xiang, H., & Wang, H. (2011). Berberine Moderates Glucose and Lipid Metabolism through Multipathway Mechanism. Evidence-Based Complementary and Alternative Medicine. https://doi.org/10.1155/2011/924851
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.